« Return to News | Drug Sponsors

Par to acquire Anchen for $410 million

Thursday, August 25, 2011 11:17 AM

Generics drug maker Par Pharmaceutical has reached an agreement to acquire privately-held Anchen Pharmaceuticals, according to PharmaTimes.

Par is prepared to part with $410 million in cash to get hold of Anchen, which specializes in extended-release and niche generics. It has five commercialized products, 27 Abbreviated New Drug Applications pending with the FDA and 26 additional products in development.

Anchen anticipates launching eight-ten niche generic products over the next two years. The Irvine, California-headquartered firm has 218 employees "and over 72,000 square feet of expandable manufacturing and warehouse facilities with state-of-the-art equipment."

Par chief executive Patrick LePore said that Anchen has "an excellent development track record and robust product pipeline, which, when combined with Par's existing capabilities and pipeline, more than doubles our product opportunities.”

The transaction is expected to be immediately accretive to earnings in 2011 and Par noted that it will finance the deal with the help of a $350 million term loan.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.